Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Focal Adhesion Kinase (FAK)

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101628

Synonyms

Historical Background

Focal adhesion kinase (FAK), a non-receptor protein-tyrosine kinase found in virtually all mammalian cells (Mitra et al. 2005; Frame et al. 2011) and crucial to integrin-based signaling (Alanko and Ivaska 2016). FAK was originally identified in 1990 as an ~125 kDa (p125/pp125) phosphoprotein (Kanner et al. 1990). FAK was later shown to be a cytosolic protein mostly accumulated at focal adhesions at the cell-matrix interface, and it was designated pp125FAK (Schaller et al. 1992). An increase in tyrosine phosphorylation of pp125FAK was detected during cell adhesion to fibronectin (Hanks et al. 1992). Furthermore, cells treated with a specific protein-tyrosine kinase inhibitor herbimycin A led to a decrease in focal adhesion and stress fiber formation (Burridge et al. 1992). These earlier observations thus illustrate that tyrosine phosphorylation of FAK plays a role in cytoskeletal organization induced by adhesion of cells onto extracellular matrix (ECM). Subsequently, protein-protein interactions between FAK and Src via the Src-homology 2 (SH2) domain (Cobb et al. 1994) and the binding of the p85 subunit of phosphatidylinositol 3-kinase (PI3K) to FAK (Chen and Guan 1994) were reported. Also, Tyr397 (Y397) in FAK was shown to be the principal autophosphorylation site, providing new insight in understanding the regulation of FAK intrinsic activity (Schaller et al. 1994). FAK knockout (KO) mice were generated in 1995 (Ilic et al. 1995), and considerably reduced motility was noted in fibroblast-like cells or mesodermal cells isolated from FAK-deficient embryos, which was likely the result of disorganized actin-based cytoskeleton in these cells (Ilic et al. 1995). Changes in actin-based cytoskeleton were shown to be associated with integrin signaling, and a direct interaction between the cytoplasmic domain of β1-integrin and FAK was demonstrated based on an in vitro study (Schaller et al. 1995). An overexpression of FAK was also noted in epithelial and mesenchymal tumors (Owens et al. 1995, 1996). Since then, studies on FAK and the associated signaling pathways under both physiological and pathological conditions have greatly expanded, and FAK has been shown to be involved in cell cycle progression (Zhao et al. 1998; Klein et al. 2009; Mui et al. 2015), cell migration (Cary et al. 1996; Sieg et al. 1999; Slack et al. 2001; Chen and Chen 2006), cell survival (Frisch et al. 1996; Ashton et al. 2010), cell proliferation (Owens et al. 2001), cell morphology (Dunty and Schaller 2002), as well as regulation of cell junctions (Siu et al. 2003, 2011; Lie et al. 2012).

Structure

FAK is comprised of three major domains along its polypeptide sequence, FERM domain, intrinsic kinase domain, and FAT domain, as shown in the schematic diagram of human FAK (Fig. 1). The N-terminal FERM (band 4.1, ezrin, radixin, moesin) domain is also found in a number of cytoskeletal-associated proteins (e.g., ezrin, radixin, moesin, talin, Janus tyrosine kinases (JAKs), protein-tyrosine phosphatases (PTPNs)) within the protein 4.1 superfamily (Chishti et al. 1998; Jung and McCarty 2012). The FERM domain in FAK consists of three subdomains called the F1, F2, and F3 which interact with multiple proteins, including tumor suppressor p53 (Lim et al. 2008), murine double minute-2 (Mdm-2) (Lim et al. 2008), ezrin (Poullet et al. 2001), Ekt (Chen et al. 2001), GATA4 transcription factor (Lim et al. 2012) and hepatocyte growth factor receptor c-Met (Chen and Chen 2006), and many others (Fig. 1). Thus, FAK can create a giant regulatory protein complex by recruiting other regulatory proteins via its FERM domain.
Focal Adhesion Kinase (FAK), Fig. 1

The different functional domains of human FAK. FAK contains an N-terminal FERM (band 4.1, ezrin, radixin, moesin) domain, a central kinase domain (KD), and a C-terminal focal adhesion targeting (FAT) domain. Some of the binding partners (red lines) on different functional domains of FAK, the commonly known tyrosine phosphorylation sites (green head pins), and the three proline-rich (PR) regions of PR1, PR2, and PR3 are shown. This figure is generated based on previous publications (Schaller et al. 1994; Han and Guan 1999; Chen et al. 2001; Poullet et al. 2001; Parsons 2003; Chen and Chen 2006; Serrels et al. 2007; Frame et al. 2010; Serrels et al. 2010). Other abbreviations used: Arp2/3 actin-related protein 2/3, WASP Wiskott-Aldrich syndrome protein, RACK1 receptors for activated C-kinase 1, GATA4 GATA-binding factor 4, Mdm-2 mouse double minute-2 homolog, VEGFR vascular endothelial growth factor receptor, SH Src homology, Graf GTPase regulator associated with focal adhesion kinase, Cas or p130 Cas Crk-associated substrate, Csk C-terminal Src kinase, GRB2 growth factor receptor-bound protein 2, Etk epithelial and endothelial tyrosine kinase, Hic-5 hydrogen peroxide-inducible clone-5

A stretch of ~160 amino acid residues at the C-terminal region of FAK constitutes the focal adhesion targeting (FAT) domain (Hildebrand et al. 1993). The FAT domain is required for efficient localization of FAK to focal adhesions at the cell-matrix interface where integrin clusters reside, partially through its interaction with other focal adhesion adaptor proteins such as paxillin (Brown et al. 1996) and talin (Chen et al. 1995). Tyr925 (Y925) in the FAT domain is a putative site to be phosphorylated by Src family kinases, and it is essential to the binding of FAK to the SH2 domain of growth factor receptor-bound protein 2 (GRB2) (Schlaepfer et al. 1994).

The intrinsic catalytic kinase domain resides in-between the FERM and the FAT domains. FERM domain and the kinase domain can form an auto-inhibitory interaction (Cooper et al. 2003), involving F2 subdomain in FERM and Phe596 on the C-terminal region of the intrinsic kinase domain (Frame et al. 2011). This inhibitory interaction hinders the activation of the catalytic kinase domain, thereby blocking the intrinsic activity of FAK. The binding of the cytoplasmic domain of β1-integrin to FAK FERM domain can disrupt the interaction between the kinase domain and FERM, thereby stimulating FAK activity.

Besides the three major domains, there are three proline-rich (PR) regions called PR1, PR2, and PR3 in FAK. The N-terminal PR1 serves as a docking site for SH3-containing proteins, whereas the C-terminal PR2 and PR3 act as binding sites for a number of other SH3 domain-containing proteins such as p130Cas (Polte and Hanks 1995) and Graf (Taylor et al. 1998).

Regulation of FAK Phosphorylation

Regulation of FAK activity is mediated by phosphorylation through at least one of the several putative phosphorylation sites in FAK as shown in Fig. 1 (Schaller et al. 1994; Parsons 2003; Frame et al. 2011). Initial activation of FAK begins with the release of FERM domain-kinase domain interaction that blocks FAK activation. Autophosphorylation of FAK on Y397 located within a linker region between the FERM and kinase domain is considered the most crucial step of FAK activation. Autophosphorylation of FAK at Y397 creates a binding site for SH2-containing proteins such as phosphatidylinositol 3-kinase (PI-3K), Grb7, and Src (Schaller et al. 1994; Xing et al. 1994; Chen et al. 1996; Han and Guan 1999). The FAK-Src complex further phosphorylates the Y576/577 site in the kinase domain, which causes conformational changes in FAK by blocking FERM domain-mediated intramolecular inhibition (Calalb et al. 1995; Cai et al. 2008). Phosphorylation of Y925 provides a binding site for the SH2 domain of GRB2, which is able to mediate ERK1/2 activation through the Ras pathway (Schlaepfer et al. 1994). Y861 is another crucial Src-mediated phosphorylation site on FAK (Calalb et al. 1996). Y861 phosphorylation may associate with enhanced cell motility (Slack et al. 2001). It also potentiates FAK phosphorylation at Y397. In this context, it is of interest to note that phosphorylation of FAK at Y407 negatively affects FAK autophosphorylation at Y397, illustrating the significant but antagonistic relationship between these two phosphorylation sites. Studies have shown that overexpression of a constitutively active p-FAK-Y397 mutant, p-FAK-Y397E, in the testis delays the timely remodeling of the F-actin-based cytoskeleton in the adluminal compartment of the seminiferous epithelium so that adhesion proteins that anchor spermatids to the epithelium (e.g., nectin 2, nectin 3) persistently remain at the Sertoli cell-spermatid interface, delaying the event of spermiation at stage VIII of the epithelial cycle in the rat testis (Wan et al. 2013). These findings thus illustrate that p-FAK-Y397 is crucial to support spermatid adhesion, consistent with earlier reports that p-FAK-Y397 is highly expressed at the Sertoli-spermatid interface until shortly before spermiation (Siu et al. 2003; Beardsley et al. 2006). Interestingly, overexpression of p-FAK-Y397E in Sertoli cells with an established functional TJ permeability barrier perturbs the TJ-barrier function, making it “leaky,” whereas overexpression of p-FAK-Y407E, a constitutively active phosphomimetic mutant of p-FAK Y407, protects the TJ-barrier function (Lie et al. 2012), illustrating p-FAK-Y397 and p-FAK-Y407 are having antagonistic effects on cell adhesion function in the testis.

It should be noted that multiple serine phosphorylation sites (e.g., S722, S840, S843, and S910) and threonine phosphorylation sites (e.g., T406) are also found in FAK (Ma et al. 2001; Grigera et al. 2005). FAK can be phosphorylated at S910 through binding of platelet-derived growth factor (PDGF) to its receptor via an ERK-dependent pathway (Hunger-Glaser et al. 2004). Cell detachment and disruption in actin cytoskeleton induced by chemicals lead to phosphorylation of FAK at S843 (Jacamo et al. 2007). Phosphorylation at S843 is able to repress FAK phosphorylation at Y397 (Jacamo et al. 2007), suggesting a cross talk between serine and tyrosine phosphorylation sites. Phosphorylation of FAK at S732 by cyclin dependent kinase 5 (Cdk5) promotes the organization of microtubule fork near the nucleus, regulating neuronal migration, and may play a role in the regulation of centrosome function during mitosis (Xie et al. 2003; Park et al. 2009).

Physiological Function

FAK is found in virtually all mammalian cells and is known to be involved in a number of normal cellular events and also in pathogenesis of diseases. These include maintenance of cell matrix and cell junction network homeostasis, blood-tissue barrier (e.g., blood-testis barrier) function, cell cycle progression, cell survival, wound healing, and carcinogenesis (Cheng and Mruk 2009; Frame et al. 2010; Alanko and Ivaska 2016; Byron and Frame 2016; Kanteti et al. 2016; Leavitt et al. 2016). These diverse functional roles of FAK in multiple cellular events are due to the extensive signaling network mediated by FAK as illustrated in Fig. 2. Herein, we summarize the role of FAK in several major cellular events in mammals.
Focal Adhesion Kinase (FAK), Fig. 2

Model of FAK signaling upon activation by integrins, growth factor receptors, and/or cytokine receptors. Shown here are some of the better studied signaling partners and/or signaling pathways involving FAK. This figure illustrates some of the major partner proteins working in concert with FAK to serve as the downstream signaling molecules to transduce signaling function following activation of the integrin-, growth factor receptor-, or cytokine receptor-based complexes. In short, FAK, together with Src, paxillin, and talin, triggers downstream signaling pathways including but not limited to PI3K/Akt/mTOR, JNK, and Rho GTPases. Disassociation of Arp2/3 complex from FAK may induce actin turnover. FAK inhibition enhances its nuclear localization. This figure is generated based on previous publications (Ling et al. 2003; Parsons 2003; Serrels et al. 2007; Cai et al. 2008; Ossovskaya et al. 2008; Frame et al. 2010; Siu et al. 2011; Lim et al. 2012). Abbreviations used: GATA4 GATA-binding factor 4, Mdm-2 mouse double minute-2 homolog, CHIP C-terminus of HSC70-interacting protein, PI3K phosphoinositide 3-kinase, JNK c-Jun N-terminal kinase, PtdIns(4,5)P 2 Phosphatidylinositol 4,5-bisphosphate, PIPKIγ type Iγ phosphatidylinositol 4-phosphate 5-kinase, RhoA Ras homolog gene family, member A, mTOR mammalian target of rapamycin

FAK in Development

FAK is expressed in virtually all mammalian cells and tissues (Schlaepfer et al. 1999; Parsons 2003). It is also highly conserved between species including Drosophila (Fox et al. 1999) and zebrafish (Henry et al. 2001). FAK plays a crucial role in early embryonic development since FAK deletion led to early embryonic lethality at embryonic day 8.5 (E8.5) (Ilic et al. 1995). Both FAK+/− and FAK−/− embryos were smaller in size vs. FAK+/+ embryos at E8.0–8.5 (Lim et al. 2008). Moreover, neither successful vasculogenesis nor angiogenesis of the vasculature was observed in FAK-null embryos. However, FAK endothelial cell (EC)-specific KO embryos were normal at E8.5, although late embryonic lethality was found in most embryos, together with increased EC death, reduced cell proliferation and migration, as well as blood vessel collapse (Shen et al. 2005). A decrease in paxillin phosphorylation and attenuation in JNK and/or Erk signaling was also reported in these FAK-null ECs (Shen et al. 2005). Collectively, these findings illustrate that FAK is required for vascular development during embryogenesis.

FAK in Cell Migration

Cell migration is a dynamic process, which includes the assembly and disassembly (i.e., remodeling) of actin-based cytoskeleton at the cell periphery especially at focal adhesions (or focal contacts). It also requires dynamic changes in the integrin-based adhesion complex such as integrin receptor clustering, internalization, and/or dissociation. The involvement of FAK in cell migration has been well documented with the initial observation that FAK phosphorylation was elevated in wounded human umbilical vein endothelial cell (HUVEC) monolayers (Romer et al. 1994), and considerably reduced motility was found in FAK-null cells (Ilic et al. 1995). Moreover, overexpression of FAK induced a marked increase in cell migration, whereas a substitution of Y397 to F, making p-FAK-Y397 a non-phosphorylatable (i.e., constitutively inactive) mutant, abolished the ability of FAK to stimulate cell migration (Cary et al. 1996). Lamellipodia are actin-based protrusions at the leading edge of a mammalian cell, such as fibroblast, macrophage, and Sertoli cell. Such mammalian cells are ideal models to identify and study signaling pathways involved in regulating cell migration (Machesky 2008). FAK is involved in lamellipodia formation since considerably fewer lamellipodia and reduced stress fibers were found in FAK-deficient embryonic fibroblasts (Serrels et al. 2007). A small fraction of endogenous FAK has been shown to form a dynamic complex with actin-related protein 2/3 (Arp2/3) complex (actin barbed-end nucleation proteins) through the F1 subdomain of FERM domain. Upon adhesion of fibroblasts to ECM, autophosphorylation of FAK at Y397 triggered by integrin signaling leads to disassociation of Arp2/3 complex from FAK. The released Arp2/3 complex is subsequently targeted to the newly formed lamellipodia, probably promoting actin nucleation from the barbed end of an actin microfilament by causing the formation of a branched actin network, whereas FAK remains at the site of focal adhesions (Serrels et al. 2007). FERM domain of FAK is also associated with neuronal Wiskott-Aldrich Syndrome protein (N-WASP) from the Wiskott-Aldrich Syndrome protein family (Wu et al. 2004; Serrels et al. 2007), which is an upstream activator of the Arp2/3 complex (Cheng and Mruk 2011). More important, FAK phosphorylates N-WASP at Y256, which inhibits nuclear localization of N-WASP but promotes its cytoplasmic accumulation, stimulating cell migration (Wu et al. 2004). Given that N-WASP activates the Arp2/3 complex (Lauffenburger and Horwitz 1996), it is likely that FAK works in concert with the Arp2/3 complex and N-WASP to regulate actin dynamics and cell migration. This possibility has been confirmed in Sertoli cells cultured in vitro with an established functional tight junction (TJ) barrier since overexpression of p-FAK-Y407E induces better structural interaction between N-WASP and the Arp2/3 complex, upregulating actin nucleation kinetics (Lie et al. 2012). In addition, FAK FERM domain also associates with receptor for activated C kinase 1 (RACK1), at a site differs from the one that interacts with Arp3 (Serrels et al. 2010). FAK co-localizes with RACK1 mainly at the transient nascent cell-matrix contact site close to the cell-substratum interface instead of mature focal adhesions of the adherent cells. A disruption in the association between FAK and RACK1 leads to RACK1 cytoplasmic localization and disappearance of actin-based cell protrusions. Collectively, these findings suggest that FAK serves as a signal mediator to relate upstream integrin-based signaling to the actin-based cytoskeleton to modulate cell migration, in particular the formation of lamellipodia.

FAK in Cell Junction Dynamics

The role of FAK in regulating cell junctions, similar to its role in cell migration, relies largely on its control over actin-based cytoskeleton. One of the best studied models for understanding the effects of FAK on cell junctions is the testis (Cheng and Mruk 2012; Li et al. 2013). In the testis, seminiferous tubules are the functional units that generate spermatozoa from undifferentiated spermatogonia through spermatogenesis. In a cross section of a seminiferous tubule, spermatogenesis takes place in the seminiferous epithelium which is composed of only male germ cells at different developmental stages and the supporting Sertoli cells (Xiao et al. 2014). Two predominant testis-specific cell junctional complexes are found in the seminiferous epithelium: the apical ectoplasmic specialization (apical ES) between steps 8–19 spermatids and Sertoli cells (Russell and Clermont 1976) and the basal ES between adjacent Sertoli cells which together with TJ, gap junction, and desmosome constitutes the blood-testis barrier (BTB) (Setchell 2008; Cheng and Mruk 2012). Unlike other epithelia where focal adhesion is formed at cell-matrix interface, there is no morphological equivalence to the ultrastructure of focal adhesion complex detected at the Sertoli cell-basement membrane interface in the testis by electron microscopy (Cheng and Mruk 2002; Mruk and Cheng 2004). In this context, it should be noted that the basement membrane is a modified form of ECM in the testis, and the only anchoring junction at the Sertoli cell-basement membrane interface is the intermediate filament-based hemidesmosome (Dym 1994; Siu and Cheng 2004). FAK, in particular p-FAK-Y397 and p-FAK-Y576, is exclusively found at the Sertoli cell-spermatid interface, whereas p-FAK-Y407 is at the Sertoli cell-cell interface at the basal ES/BTB but also apical ES in the adult rat testis (Siu et al. 2003; Lie et al. 2012). Studies have shown that p-FAK-Y397 forms a giant protein complex with the apical ES-associated proteins, including β1-integrin, c-Src, vinculin, p130Cas, PI-3K, RhoA, and GTPase (Siu et al. 2003, 2005, 2011), illustrating that this p-FAK-Y397-based protein complex may be crucial to the β1-integrin-based signaling at the apical ES. This concept is supported by findings that p-FAK-Y397 is an integrated component of the α6β1-integrin-based adhesion complex at the apical ES, which is persistently found at the apical ES until at the very late stage VIII tubules, plausibly involved in the release of mature spermatids (i.e., spermatozoa) during spermiation (Beardsley et al. 2006; O’Donnell et al. 2011). In this context, it is of interest to note that unlike p-FAK-Y397 which localizes at the dorsal (convex) side of the spermatid head, p-FAK-Y407 is expressed at the ventral (concave) side of the spermatid head and co-localizes with Arp3 (Lie et al. 2012) and also Eps8, an actin barbed-end capping and bundling protein, in the testis (Lie et al. 2009). Given the functional connection between FAK and the Arp2/3 complex as noted above, it is likely that the interactions between p-FAK-Y397 (and/or p-FAK-Y407) with the Arp2/3 complex can modulate the organization of actin microfilaments at the apical ES, determining if these filaments should remain in a bundled versus an unbundled/branched configuration. At the BTB, the predominant form of phosphorylated FAK is p-FAK-Y407 (Lie et al. 2012). A knockdown of FAK in Sertoli cells with an established functional TJ barrier by RNAi using FAK-specific siRNA duplexes causes a disruption of the TJ barrier (Siu et al. 2009). The protective effect of FAK on the Sertoli cell TJ-barrier function has been clearly demonstrated in a study in which overexpression of a constitutively active p-FAK-Y407 mutant (p-FAK-Y407E) promotes the Sertoli cell TJ barrier (Lie et al. 2012). Additionally, in a study using a toxicant model in which treatment of Sertoli cells cultured in vitro with an established functional TJ barrier with perfluorooctanesulfonate (PFOS) downregulates p-FAK-Y407, but not p-FAK-Y397, a disruption of the actin microfilaments in the Sertoli cell cytosol is also observed (Wan et al. 2014). However, overexpression of the p-FAK-Y407E rescues the PFOS-mediated Sertoli cell TJ-barrier disruption by “resealing” the disrupted TJ barrier and also rescues the PFOS-induced microfilament truncation by making the F-actin network more similar to control Sertoli cells (Wan et al. 2014). In short, these findings illustrate the physiological significance of FAK in testis function, in particular BTB dynamics.

FAK Nuclear Localization

The FERM domain in particular the F2 subdomain is responsible for FAK nuclear localization (Lim et al. 2008). In HUVEC, approximately 5–10% of FAK is nuclear associated (Lim et al. 2008). FAK represses p53 expression independent of its catalytic activity. It has been suggested that FAK in the nucleus acts as a scaffold to stabilize tumor suppressor p53 and Mdm2 (murine double minute-2, a ubiquitin E3 ligase that regulates p53 levels in cells (Iwakuma and Lozano 2003)), causing p53 ubiquitination and subsequent p53 degradation (Lim et al. 2008). Moreover, the use of a FAK-specific inhibitor FAK-I also enhances nuclear targeting of FAK, concomitant with a loss of GATA4 expression in the nucleus (Lim et al. 2012). It is likely that nuclear-accumulated FAK is involved in GATA4 poly-ubiquitination (Lim et al. 2012) and subsequent GATA4 degradation. Interestingly, two nuclear export signal sequences with one located within the FERM domain and the other within the kinase domain are found in FAK (Ossovskaya et al. 2008), although the detailed mechanism(s) that regulates nucleocytoplasmic shuttling of FAK remains to be investigated.

Pathological Function

FAK is also involved in the pathogenesis of a number of diseases, most notably carcinogenesis. Here is a brief summary of the findings regarding the role of FAK in cancer biology and other pathological conditions.

FAK in Cancer

FAK mutations, phosphorylation, and overexpression have been implicated in tumor progression and metastasis (Owens et al. 1995, 1996; Pylayeva et al. 2009; Park et al. 2010; Yom et al. 2011; Yoon et al. 2014). For instance, a deletion of the entire exon 33 of FAK transcript has been identified in some cancerous tissues (Fang et al. 2014). An increase in metastatic potential in invasive human prostate cancer cells correlates with an upregulation of FAK expression, plus an overall increase in tyrosine phosphorylation on Y397 and intrinsic FAK activity (Slack et al. 2001). Due to the inherent effects of FAK in modulating cell movement and cell adhesion as discussed above, it is not unexpected that an upregulation on FAK expression or its overall enhanced intrinsic activity positively correlates with the potential in cancer metastasis. Additionally, because of the intimate functional and structural association between FAK and Src, these two non-receptor protein kinases (and oncogenes) are also the therapeutic target of chemotherapy (Brunton and Frame 2008; Kratimenos et al. 2014).

Apart from its involvement in regulating cell adhesion and migration, the ability of FAK to promote cell survival also confers its supporting role in tumorigenesis. Specific KO of FAK in skin tissues hinders chemically induced, Ras-dependent papilloma (a benign epithelial tumor) formation, and FAK deletion from benign papillomas leads to an upregulation of caspase 3, an apoptosis indicator (McLean et al. 2004). Furthermore, cell adhesion-independent but FADD (Fas-associated death domain)-, caspase 8-, and/or caspase 3-dependent apoptosis is noted in human breast cancer cells following perturbed FAK function and degradation of FAK (Xu et al. 2000). The role of FAK to support cancer cell survival is further confirmed in a study in which deletion of FAK considerably reduces the number of newly formed breast tumors induced by p53 deletion or p53 point mutation (van Miltenburg et al. 2014), suggesting FAK as a crucial regulator of mammary epithelial cell proliferation and survival in p53-mediated mammary tumor development. The ability of FAK to maintain tumor cell proliferation may be partly due to Src-mediated phosphorylation of p130Cas since expression of a dominant negative form of p130Cas prevents FAK-mediated tumor cell proliferation and knockdown of FAK or p130Cas leads to growth arrest of breast cancer cells in a Ras- or PI3K-dependent fashion (Pylayeva et al. 2009).

Another likely mechanism by which FAK promotes tumorigenesis relies on its ability to maintain cancer stem/progenitor cell population since targeted ablation of FAK in mammary epithelium reduces the pool of cancer stem/progenitor cells in primary tumors and impairs their self-renewal and migration (Luo et al. 2009). Cancer stem cells (CSCs) are rare cells with proliferative potential capable of promoting tumor formation and growth (Reya et al. 2001; Jayachandran et al. 2016). A group of CSCs found along the tumor-stroma interface in cutaneous squamous cell carcinomas show high α6β1-integrin expression. TGF-β/TβRII and integrin/FAK signaling act in opposing manner to control the self-renewal and tumor-initiation capabilities of those CSCs with high CD34 expression (Schober and Fuchs 2011).

The pathological significance of FAK in tumor formation and metastasis makes it an important target for the development of cancer therapeutics. A number of FAK inhibitors have been developed and probed for their suitability as anticancer drugs (Figel and Gelman 2011; Kanteti et al. 2016). For instance, an ATP analog TAE-226 from Novartis is a low molecular weight FAK inhibitor earlier shown to inhibit glimoa cell proliferation and adhesion (Shi et al. 2007). PF-573,228 from Pfizer is another ATP analog capable of hindering the migration of REF52 fibroblasts dose dependently (Slack-Davis et al. 2007). Some of these inhibitors have displayed promising antitumor activities in clinical trials (Infante et al. 2012; Yoon et al. 2014).

FAK in Other Pathological Conditions

FAK is required for intestinal regeneration following 14 Gy γ-irradiation since almost no signs of proper regeneration were detected in the small intestines of FAK-deficient mice (Ashton et al. 2010). However, activation of Akt signaling pathway, independently of FAK, is able to rescue the failed regeneration caused by FAK deletion, illustrating that Akt signaling may be an integrated component of the FAK signaling network as illustrated in Fig. 2. Moreover, phosphorylation of mTOR, the downstream signaling molecule of Akts, is also considerably downregulated in FAK knockout models (Ashton et al. 2010). Thus, it is likely that FAK plays an important role in intestinal regeneration via the Akt/mTOR signaling pathway.

Summary

FAK is a self-regulating scaffolding protein and non-receptor protein-tyrosine kinase that binds to a number of receptors, kinases, lipids, and other regulatory proteins through its FERM domain, FAT domain, and proline-rich regions, creating a giant regulatory protein complex in mammalian cells/epithelia in response to changes in environment. Its autophosphorylation and interactions with other biochemical complexes are vital for signaling output and cell fate under both physiological and pathological conditions. Due to the multiple roles of FAK in regulating cell adhesion, migration, proliferation, and survival, as well as junction dynamics, FAK is also a crucial target for clinical therapies especially chemotherapy for different cancers. Emerging evidence has shown that FAK exerts its regulatory function inside the nucleus also offers new possibilities for enhancing FAK translocation into the nucleus to modulate transcriptional regulation of genes. An expanded research on FAK will likely bring new treatment to many diseases in the years to come.

Notes

Acknowledgments

This work was supported by grants from the National Institutes of Health, NICHD, R01 HD056034 to C.Y. C., and U54 HD029990 Project 5 to C.Y.C.

References

  1. Alanko J, Ivaska J. Endosomes: emerging platforms for integrin-mediated FAK signalling. Trends Cell Biol. 2016;26:391–8.PubMedCrossRefGoogle Scholar
  2. Ashton GH, Morton JP, Myant K, Phesse TJ, Ridgway RA, Marsh V, et al. Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling. Dev Cell. 2010;19:259–69.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Beardsley A, Robertson DM, O’Donnell L. A complex containing alpha6beta1-integrin and phosphorylated focal adhesion kinase between Sertoli cells and elongated spermatids during spermatid release from the seminiferous epithelium. J Endocrinol. 2006;190:759–70.PubMedCrossRefGoogle Scholar
  4. Brown MC, Perrotta JA, Turner CE. Identification of LIM3 as the principal determinant of paxillin focal adhesion localization and characterization of a novel motif on paxillin directing vinculin and focal adhesion kinase binding. J Cell Biol. 1996;135:1109–23.PubMedCrossRefGoogle Scholar
  5. Brunton VG, Frame MC. Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol. 2008;8:427–32.PubMedCrossRefGoogle Scholar
  6. Burridge K, Turner CE, Romer LH. Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. J Cell Biol. 1992;119:893–903.PubMedCrossRefGoogle Scholar
  7. Byron A, Frame MC. Adhesion protein networks reveal functions proximal and distal to cell-matrix contacts. Curr Opin Cell Biol. 2016;39:93–100.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Cai X, Lietha D, Ceccarelli DF, Karginov AV, Rajfur Z, Jacobson K, et al. Spatial and temporal regulation of focal adhesion kinase activity in living cells. Mol Cell Biol. 2008;28:201–14.PubMedCrossRefGoogle Scholar
  9. Calalb MB, Polte TR, Hanks SK. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol. 1995;15:954–63.PubMedPubMedCentralCrossRefGoogle Scholar
  10. Calalb MB, Zhang X, Polte TR, Hanks SK. Focal adhesion kinase tyrosine-861 is a major site of phosphorylation by Src. Biochem Biophys Res Commun. 1996;228:662–8.PubMedCrossRefGoogle Scholar
  11. Cary LA, Chang JF, Guan JL. Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. J Cell Sci. 1996;109(Pt 7):1787–94.PubMedGoogle Scholar
  12. Chen HC, Appeddu PA, Isoda H, Guan JL. Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J Biol Chem. 1996;271:26329–34.PubMedCrossRefGoogle Scholar
  13. Chen HC, Appeddu PA, Parsons JT, Hildebrand JD, Schaller MD, Guan JL. Interaction of focal adhesion kinase with cytoskeletal protein talin. J Biol Chem. 1995;270:16995–9.PubMedCrossRefGoogle Scholar
  14. Chen HC, Guan JL. Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A. 1994;91:10148–52.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Chen R, Kim O, Li M, Xiong X, Guan JL, Kung HJ, et al. Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain. Nat Cell Biol. 2001;3:439–44.PubMedCrossRefGoogle Scholar
  16. Chen SY, Chen HC. Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion. Mol Cell Biol. 2006;26:5155–67.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Cheng CY, Mruk DD. The blood-testis barrier and its implication in male contraception. Pharmacol Rev. 2012;64:16–64.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Cheng CY, Mruk DD. Cell junction dynamics in the testis: Sertoli-germ cell interactions and male contraceptive development. Physiol Rev. 2002;82:825–74.PubMedCrossRefGoogle Scholar
  19. Cheng CY, Mruk DD. Regulation of blood-testis barrier dynamics by focal adhesion kinase (FAK). An unexpected turn of events. Cell Cycle. 2009;8:3493–9.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Cheng CY, Mruk DD. Regulation of spermiogenesis, spermiation and blood-testis barrier dynamics: novel insights from studies on Eps8 and Arp3. Biochem J. 2011;435:553–62.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Chishti AH, Kim AC, Marfatia SM, Lutchman M, Hanspal M, Jindal H, et al. The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem Sci. 1998;23:281–2.PubMedCrossRefGoogle Scholar
  22. Cobb BS, Schaller MD, Leu TH, Parsons JT. Stable association of pp60src and pp59fyn with the focal adhesion-associated protein tyrosine kinase, pp125FAK. Mol Cell Biol. 1994;14:147–55.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Cooper LA, Shen TL, Guan JL. Regulation of focal adhesion kinase by its amino-terminal domain through an autoinhibitory interaction. Mol Cell Biol. 2003;23:8030–41.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Dunty JM, Schaller MD. The N termini of focal adhesion kinase family members regulate substrate phosphorylation, localization, and cell morphology. J Biol Chem. 2002;277:45644–54.PubMedCrossRefGoogle Scholar
  25. Dym M. Basement membrane regulation of Sertoli cells. Endocr Rev. 1994;15:102–15.PubMedGoogle Scholar
  26. Fang XQ, Liu XF, Yao L, Chen CQ, ZD G, Ni PH, et al. Somatic mutational analysis of FAK in breast cancer: a novel gain-of-function mutation due to deletion of exon 33. Biochem Biophys Res Commun. 2014;443:363–9.PubMedCrossRefGoogle Scholar
  27. Figel S, Gelman IH. Focal adhesion kinase controls prostate cancer progression via intrinsic kinase and scaffolding functions. Anticancer Agents Med Chem. 2011;11:607–16.PubMedCrossRefGoogle Scholar
  28. Fox GL, Rebay I, Hynes RO. Expression of DFak56, a Drosophila homolog of vertebrate focal adhesion kinase, supports a role in cell migration in vivo. Proc Natl Acad Sci U S A. 1999;96:14978–83.PubMedPubMedCentralCrossRefGoogle Scholar
  29. Frame MC, Patel H, Serrels B, Lietha D, Eck MJ. The FERM domain: organizing the structure and function of FAK. Nat Rev Mol Cell Biol. 2011;11:802–14.CrossRefGoogle Scholar
  30. Frame MC, Patel H, Serrels B, Lietha D, Eck MJ. The FERM domain: organizing the structure and function of FAK. Nat Rev Mol Cell Biol. 2010;11:802–14.PubMedCrossRefGoogle Scholar
  31. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol. 1996;134:793–9.PubMedCrossRefGoogle Scholar
  32. Grigera PR, Jeffery ED, Martin KH, Shabanowitz J, Hunt DF, Parsons JTFAK. phosphorylation sites mapped by mass spectrometry. J Cell Sci. 2005;118:4931–5.PubMedCrossRefGoogle Scholar
  33. Han DC, Guan JL. Association of focal adhesion kinase with Grb7 and its role in cell migration. J Biol Chem. 1999;274:24425–30.PubMedCrossRefGoogle Scholar
  34. Hanks SK, Calalb MB, Harper MC, Patel SK. Focal adhesion protein-tyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci U S A. 1992;89:8487–91.PubMedPubMedCentralCrossRefGoogle Scholar
  35. Henry CA, Crawford BD, Yan YL, Postlethwait J, Cooper MS, Hille MB. Roles for zebrafish focal adhesion kinase in notochord and somite morphogenesis. Dev Biol. 2001;240:474–87.PubMedCrossRefGoogle Scholar
  36. Hildebrand JD, Schaller MD, Parsons JT. Identification of sequences required for the efficient localization of the focal adhesion kinase, pp125FAK, to cellular focal adhesions. J Cell Biol. 1993;123:993–1005.PubMedCrossRefGoogle Scholar
  37. Hunger-Glaser I, Fan RS, Perez-Salazar E, Rozengurt E. PDGF and FGF induce focal adhesion kinase (FAK) phosphorylation at Ser-910: dissociation from Tyr-397 phosphorylation and requirement for ERK activation. J Cell Physiol. 2004;200:213–22.PubMedCrossRefGoogle Scholar
  38. Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature. 1995;377:539–44.PubMedCrossRefGoogle Scholar
  39. Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol. 2012;30:1527–33.PubMedCrossRefGoogle Scholar
  40. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res. 2003;1:993–1000.PubMedGoogle Scholar
  41. Jacamo R, Jiang X, Lunn JA, Rozengurt E. FAK phosphorylation at Ser-843 inhibits Tyr-397 phosphorylation, cell spreading and migration. J Cell Physiol. 2007;210:436–44.PubMedCrossRefGoogle Scholar
  42. Jayachandran A, Dhungel B, Steel JC. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol. 2016;9:74.PubMedPubMedCentralCrossRefGoogle Scholar
  43. Jung Y, McCarty JH. Band 4.1 proteins regulate integrin-dependent cell spreading. Biochem Biophys Res Commun. 2012;426:578–84.PubMedPubMedCentralCrossRefGoogle Scholar
  44. Kanner SB, Reynolds AB, Vines RR, Parsons JT. Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc Natl Acad Sci U S A. 1990;87:3328–32.PubMedPubMedCentralCrossRefGoogle Scholar
  45. Kanteti R, Batra SK, Lennon FE, Salgia R. FAK and paxillin, two potential targets in pancreatic cancer. Oncotarget. 2016.Google Scholar
  46. Klein EA, Yin L, Kothapalli D, Castagnino P, Byfield FJ, Xu T, et al. Cell-cycle control by physiological matrix elasticity and in vivo tissue stiffening. Curr Biol. 2009;19:1511–8.PubMedPubMedCentralCrossRefGoogle Scholar
  47. Kratimenos P, Koutroulis I, Marconi D, Syriopoulou V, Delivoria-Papadopoulos M, Chrousos GP, et al. Multi-targeted molecular therapeutic approach in aggressive neuroblastoma: the effect of Focal Adhesion Kinase–Src–Paxillin system. Expert Opin Ther Targets. 2014;18:1395–406.PubMedGoogle Scholar
  48. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell. 1996;84:359–69.PubMedCrossRefGoogle Scholar
  49. Leavitt T, MS H, Marshall CD, Barnes LA, Lorenz HP, Longaker MT. Scarless wound healing: finding the right cells and signals. Cell Tissue Res. 2016;365:483–93.PubMedPubMedCentralCrossRefGoogle Scholar
  50. Li SY, Mruk DD, Cheng CY. Focal adhesion kinase is a regulator of F-actin dynamics: New insights from studies in the testis. Spermatogenesis. 2013;3:e25385.PubMedPubMedCentralCrossRefGoogle Scholar
  51. Lie PPY, Mruk DD, Lee WM, Cheng CY. Epidermal growth factor receptor pathway substrate 8 (Eps8) is a novel regulator of cell adhesion and the blood-testis barrier integrity in the seminiferous epithelium. FASEB J. 2009;23:2555–67.PubMedPubMedCentralCrossRefGoogle Scholar
  52. Lie PPY, Mruk DD, Mok KW, Su L, Lee WM, Cheng CY. Focal adhesion kinase-Tyr407 and -Tyr397 exhibit antagonistic effects on blood-testis barrier dynamics in the rat. Proc Natl Acad Sci U S A. 2012;109:12562–7.PubMedPubMedCentralCrossRefGoogle Scholar
  53. Lim ST, Chen XL, Lim Y, Hanson DA, Vo TT, Howerton K, et al. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell. 2008;29:9–22.PubMedPubMedCentralCrossRefGoogle Scholar
  54. Lim ST, Miller NL, Chen XL, Tancioni I, Walsh CT, Lawson C, et al. Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression. J Cell Biol. 2012;197:907–19.PubMedPubMedCentralCrossRefGoogle Scholar
  55. Ling K, Doughman RL, Iyer VV, Firestone AJ, Bairstow SF, Mosher DF, et al. Tyrosine phosphorylation of type Igamma phosphatidylinositol phosphate kinase by Src regulates an integrin-talin switch. J Cell Biol. 2003;163:1339–49.Google Scholar
  56. Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, et al. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res. 2009;69:466–74.PubMedPubMedCentralCrossRefGoogle Scholar
  57. Ma A, Richardson A, Schaefer EM, Parsons JT. Serine phosphorylation of focal adhesion kinase in interphase and mitosis: a possible role in modulating binding to p130(Cas). Mol Biol Cell. 2001;12:1–12.PubMedPubMedCentralCrossRefGoogle Scholar
  58. Machesky LM. Lamellipodia and filopodia in metastasis and invasion. FEBS Lett. 2008;582:2102–11.PubMedCrossRefGoogle Scholar
  59. McLean GW, Komiyama NH, Serrels B, Asano H, Reynolds L, Conti F, et al. Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes Dev. 2004;18:2998–3003.PubMedPubMedCentralCrossRefGoogle Scholar
  60. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nature Rev Mol Cell Biol. 2005;6:56–68.Google Scholar
  61. Mruk DD, Cheng CY. Sertoli-Sertoli and Sertoli-germ cell interactions and their significance in germ cell movement in the seminiferous epithelium during spermatogenesis. Endocr Rev. 2004;25:747–806.PubMedCrossRefGoogle Scholar
  62. Mui KL, Bae YH, Gao L, Liu SL, Xu T, Radice GL, et al. N-Cadherin Induction by ECM Stiffness and FAK Overrides the Spreading Requirement for Proliferation of Vascular Smooth Muscle Cells. Cell Rep. 2015.Google Scholar
  63. O’Donnell L, Nicholls PK, O’Bryan MK, McLachlan RI, Stanton PG. Spermiation: the process of sperm release. Spermatogenesis. 2011;1:14–35.PubMedPubMedCentralCrossRefGoogle Scholar
  64. Ossovskaya V, Lim ST, Ota N, Schlaepfer DD, Ilic DFAK. nuclear export signal sequences. FEBS Lett. 2008;582:2402–6.PubMedPubMedCentralCrossRefGoogle Scholar
  65. Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L, et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 1995;55:2752–5.PubMedGoogle Scholar
  66. Owens LV, Xu L, Dent GA, Yang X, Sturge GC, Craven RJ, et al. Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol. 1996;3:100–5.PubMedCrossRefGoogle Scholar
  67. Owens LV, Xu L, Marston WA, Yang X, Farber MA, Iacocca MV, et al. Overexpression of the focal adhesion kinase (p125FAK) in the vascular smooth muscle cells of intimal hyperplasia. J Vasc Surg. 2001;34:344–9.PubMedCrossRefGoogle Scholar
  68. Park AY, Shen TL, Chien S, Guan JL. Role of focal adhesion kinase Ser-732 phosphorylation in centrosome function during mitosis. J Biol Chem. 2009;284:9418–25.PubMedPubMedCentralCrossRefGoogle Scholar
  69. Park JH, Lee BL, Yoon J, Kim J, Kim MA, Yang HK, et al. Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer. Hum Pathol. 2010;41:1664–73.PubMedCrossRefGoogle Scholar
  70. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci. 2003;116:1409–16.PubMedCrossRefGoogle Scholar
  71. Polte TR, Hanks SK. Interaction between focal adhesion kinase and Crk-associated tyrosine kinase substrate p130Cas. Proc Natl Acad Sci U S A. 1995;92:10678–82.PubMedPubMedCentralCrossRefGoogle Scholar
  72. Poullet P, Gautreau A, Kadare G, Girault JA, Louvard D, Arpin M. Ezrin interacts with focal adhesion kinase and induces its activation independently of cell-matrix adhesion. J Biol Chem. 2001;276:37686–91.PubMedCrossRefGoogle Scholar
  73. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest. 2009;119:252–66.PubMedPubMedCentralGoogle Scholar
  74. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–11.PubMedCrossRefGoogle Scholar
  75. Romer LH, McLean N, Turner CE, Burridge K. Tyrosine kinase activity, cytoskeletal organization, and motility in human vascular endothelial cells. Mol Biol Cell. 1994;5:349–61.PubMedPubMedCentralCrossRefGoogle Scholar
  76. Russell L, Clermont Y. Anchoring device between Sertoli cells and late spermatids in rat seminiferous tubules. Anat Rec. 1976;185:259–78.PubMedCrossRefGoogle Scholar
  77. Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci U S A. 1992;89:5192–6.PubMedPubMedCentralCrossRefGoogle Scholar
  78. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol. 1994;14:1680–8.PubMedPubMedCentralCrossRefGoogle Scholar
  79. Schaller MD, Otey CA, Hildebrand JD, Parsons JT. Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. J Cell Biol. 1995;130:1181–7.PubMedCrossRefGoogle Scholar
  80. Schlaepfer DD, Hanks SK, Hunter T, van der Geer P. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature. 1994;372:786–91.PubMedCrossRefGoogle Scholar
  81. Schlaepfer DD, Hauck CR, Sieg DJ. Signaling through focal adhesion kinase. Prog Biophys Mol Biol. 1999;71:435–78.PubMedCrossRefGoogle Scholar
  82. Schober M, Fuchs E. Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-beta and integrin/focal adhesion kinase (FAK) signaling. Proc Natl Acad Sci U S A. 2011;108:10544–9.PubMedPubMedCentralCrossRefGoogle Scholar
  83. Serrels B, Sandilands E, Serrels A, Baillie G, Houslay MD, Brunton VG, et al. A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity. Curr Biol. 2010;20:1086–92.PubMedCrossRefGoogle Scholar
  84. Serrels B, Serrels A, Brunton VG, Holt M, McLean GW, Gray CH, et al. Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2/3 complex. Nat Cell Biology. 2007;9:1046–1056.Google Scholar
  85. Setchell BP. Blood-testis barrier, functional and transport proteins and spermatogenesis. Adv Exp Med Biol. 2008;636:212–33.PubMedCrossRefGoogle Scholar
  86. Shen TL, Park AY, Alcaraz A, Peng X, Jang I, Koni P, et al. Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol. 2005;169:941–52.PubMedPubMedCentralCrossRefGoogle Scholar
  87. Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, et al. A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog. 2007;46:488–96.PubMedCrossRefGoogle Scholar
  88. Sieg DJ, Hauck CR, Schlaepfer DD. Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci. 1999;112(Pt 16):2677–91.PubMedGoogle Scholar
  89. Siu ER, Wong EWP, Mruk DD, Porto CS, Cheng CY. Focal adhesion kinase is a blood-testis barrier regulator. Proc Natl Acad Sci U S A. 2009;106:9298–303.PubMedPubMedCentralCrossRefGoogle Scholar
  90. Siu MK, Mruk DD, Lee WM, Cheng CY. Adhering junction dynamics in the testis are regulated by an interplay of beta 1-integrin and focal adhesion complex-associated proteins. Endocrinology. 2003;144:2141–63.PubMedCrossRefGoogle Scholar
  91. Siu MKY, Cheng CY. Dynamic cross-talk between cells and the extracellular matrix in the testis. BioEssays. 2004;26:978–92.PubMedCrossRefGoogle Scholar
  92. Siu MKY, Wong CH, Lee WM, Cheng CY. Sertoli-germ cell anchoring junction dynamics in the testis are regulated by an interplay of lipid and protein kinases. J Biol Chem. 2005;280:25029–47.PubMedCrossRefGoogle Scholar
  93. Siu MKY, Wong CH, Xia W, Mruk DD, Lee WM, Cheng CY. The β1-integrin-p-FAK-p130Cas-DOCK180-RhoA-vinculin is a novel regulatory protein complex at the apical ectoplasmic specialization in adult rat testes. Spermatogenesis. 2011;1:73–86.PubMedPubMedCentralCrossRefGoogle Scholar
  94. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007;282:14845–52.PubMedCrossRefGoogle Scholar
  95. Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE, Parsons JT. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene. 2001;20:1152–63.PubMedCrossRefGoogle Scholar
  96. Taylor JM, Hildebrand JD, Mack CP, Cox ME, Parsons JT. Characterization of graf, the GTPase-activating protein for rho associated with focal adhesion kinase. Phosphorylation and possible regulation by mitogen-activated protein kinase. J Biol Chem. 1998;273:8063–70.PubMedCrossRefGoogle Scholar
  97. van Miltenburg MH, van Nimwegen MJ, Tijdens I, Lalai R, Kuiper R, Klarenbeek S, et al. Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation. Br J Cancer. 2014;110:2747–55.PubMedPubMedCentralCrossRefGoogle Scholar
  98. Wan HT, Mruk DD, Li SYT, Mok KW, Lee WM, Wong CKC, et al. p-FAK-Tyr397 regulates spermatid adhesion in the rat testis via its effects on F-actin organization at the ectoplasmic specialization. Am J Physiol Endocrinol Metab. 2013;305:E687–E99.PubMedPubMedCentralCrossRefGoogle Scholar
  99. Wan HT, Mruk DD, Wong CK, Cheng CY. Perfluorooctanesulfonate (PFOS) perturbs male rat Sertoli cell blood-testis barrier function by affecting F-actin organization via p-FAK-Tyr(407): an in vitro study. Endocrinology. 2014;155:249–62.PubMedCrossRefGoogle Scholar
  100. Wu X, Suetsugu S, Cooper LA, Takenawa T, Guan JL. Focal adhesion kinase regulation of N-WASP subcellular localization and function. J Biol Chem. 2004;279:9565–76.PubMedCrossRefGoogle Scholar
  101. Xiao X, Mruk DD, Wong CK, Cheng CY. Germ cell transport across the seminiferous epithelium during spermatogenesis. Physiology (Bethesda). 2014;29:286–98.Google Scholar
  102. Xie Z, Sanada K, Samuels BA, Shih H, Tsai LH. Serine 732 phosphorylation of FAK by Cdk5 is important for microtubule organization, nuclear movement, and neuronal migration. Cell. 2003;114:469–82.PubMedCrossRefGoogle Scholar
  103. Xing Z, Chen HC, Nowlen JK, Taylor SJ, Shalloway D, Guan JL. Direct interaction of v-Src with the focal adhesion kinase mediated by the Src SH2 domain. Mol Biol Cell. 1994;5:413–21.PubMedPubMedCentralCrossRefGoogle Scholar
  104. Xu LH, Yang X, Bradham CA, Brenner DA, Baldwin Jr AS, Craven RJ, et al. The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways. J Biol Chem. 2000;275:30597–604.PubMedCrossRefGoogle Scholar
  105. Yom CK, Noh DY, Kim WH, Kim HS. Clinical significance of high focal adhesion kinase gene copy number and overexpression in invasive breast cancer. Breast Cancer Res Treat. 2011;128:647–55.PubMedCrossRefGoogle Scholar
  106. Yoon H, Dehart JP, Murphy JM, Lim ST. Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights. J Histochem Cytochem. 2014;63:114–28.PubMedPubMedCentralCrossRefGoogle Scholar
  107. Zhao JH, Reiske H, Guan JL. Regulation of the cell cycle by focal adhesion kinase. J Cell Biol. 1998;143:1997–2008.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.The Mary M. Wohlford Laboratory for Male Contraceptive Research, Center for Biomedical Research, Population CouncilNew YorkUSA